XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.22.1

Segments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Summary of Segment Profit |
|  | Three months ended March 31, |
|  | 2022 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 1,737 |  |  | $ | 1,156 |  |  | $ | 492 |
Gross profit |  |  | 890 |  |  |  | 694 |  |  |  | 286 |
R&D expenses |  |  | 143 |  |  |  | 58 |  |  |  | 20 |
S&M expenses |  |  | 245 |  |  |  | 196 |  |  |  | 97 |
G&A expenses |  |  | 112 |  |  |  | 59 |  |  |  | 29 |
Other income |  |  | (11 | ) |  |  | § |  |  |  | (40 | )
Segment profit |  | $ | 402 |  |  | $ | 381 |  |  | $ | 179 |
§ Represents an amount less than $0.5 million.
|  | Three months ended March 31, |
|  | 2021 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 1,989 |  |  | $ | 1,214 |  |  | $ | 490 |
Gross profit |  |  | 1,074 |  |  |  | 688 |  |  |  | 260 |
R&D expenses |  |  | 160 |  |  |  | 66 |  |  |  | 18 |
S&M expenses |  |  | 229 |  |  |  | 214 |  |  |  | 96 |
G&A expenses |  |  | 111 |  |  |  | 70 |  |  |  | 26 |
Other income |  |  | (3 | ) |  |  | § |  |  |  | (2 | )
Segment profit |  | $ | 577 |  |  | $ | 338 |  |  | $ | 122 |
§ Represents an amount less than $0.5 million.
Schedule Of Consolidated Income Before Income Tax | The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2022 and 2021:
|  | Three months ended |
|  | March 31, |
|  | 2022 |  |  | 2021 |
|  | (U.S. $ in millions) |
North America profit |  | $ | 402 |  |  | $ | 577 |
Europe profit |  |  | 381 |  |  |  | 338 |
International Markets profit |  |  | 179 |  |  |  | 122 |
Total reportable segments profit |  |  | 962 |  |  |  | 1,036 |
Profit of other activities |  |  | 52 |  |  |  | 41 |
Total segments profit |  |  | 1,013 |  |  |  | 1,077 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |
Amortization |  |  | 200 |  |  |  | 242 |
Other assets impairments, restructuring and other items |  |  | 128 |  |  |  | 137 |
Intangible asset s impairments |  |  | 149 |  |  |  | 79 |
Legal settlements and loss contingencies |  |  | 1,124 |  |  |  | 104 |
Other unallocated amounts |  |  | 127 |  |  |  | 82 |
Consolidated operating income (loss) |  |  | (713 | ) |  |  | 434 |
Financial expenses, net |  |  | 258 |  |  |  | 290 |
Consolidated income (loss) before income taxes |  | $ | (971 | ) |  | $ | 144 |
Schedule of Net Sales by Product Line |
North America |  | Three months ended March 31, |
|  | 2022 |  |  | 2021 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 899 |  |  | $ | 1,053 |
AJOVY |  |  | 36 |  |  |  | 31 |
AUSTEDO |  |  | 154 |  |  |  | 146 |
BENDEKA ® /TREANDA ® |  |  | 82 |  |  |  | 91 |
COPAXONE |  |  | 86 |  |  |  | 164 |
Anda |  |  | 342 |  |  |  | 289 |
Other |  |  | 139 |  |  |  | 215 |
Total |  | $ | 1,737 |  |  | $ | 1,989 |
Europe |  | Three months ended March 31, |
|  | 2022 |  |  | 2021 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 876 |  |  | $ | 865 |
AJOVY |  |  | 30 |  |  |  | 16 |
COPAXONE |  |  | 72 |  |  |  | 100 |
Respiratory products |  |  | 71 |  |  |  | 93 |
Other |  |  | 107 |  |  |  | 140 |
Total |  | $ | 1,156 |  |  | $ | 1,214 |
International markets |  | Three months ended March 31, |
|  | 2022 |  |  | 2021 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 388 |  |  | $ | 392 |
AJOVY |  |  | 6 |  |  |  | 1 |
COPAXONE |  |  | 10 |  |  |  | 12 |
Other |  |  | 88 |  |  |  | 85 |
Total |  | $ | 492 |  |  | $ | 490 |

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration